Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Gao Y, Liu Y, Wang Y, Zhang Q, Wu D, Ye X, Wu J, Xu W, Zhou J, Yang Y, Cen H, Zhang F, Xiang Y, Tang X, Ding K, Lin J, Ma L, Wang S, Yu H, Zhao Y, Song B, Lv F, Huang H.
Gao Y, et al. Among authors: cen h.
Cancer. 2023 Feb 15;129(4):551-559. doi: 10.1002/cncr.34544. Epub 2022 Dec 21.
Cancer. 2023.
PMID: 36541221
Free article.